Current landscape and future of dual anti CTLA4 and PD 1/PD L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non small cell lung cancer (NSCLC)
Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre clinical studies evaluating immune checkpoint inhibitors in various cancer cell lines has suggested that combinatorial approaches may have superior survival outcomes compared to single agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti PD 1/PD L1 plus anti CTLA 4 immune checkpoint inhibitors have documented considerable advantages in survival indices over single agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual immune checkpoint inhibition with anti programmed death receptor 1/programmed cell death receptor ligand 1 (anti PD 1/PD L1) plus anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti PD 1/PD L1 plus anti CTLA 4 MoAbs for patients with melanoma and non small cell lung cancer (NSCLC) We present a synopsis of the prospects for expanding the indications of dual immune checkpoint inhibition therapy to a more diverse set of tumor histologies.
Journal of Immunotherapy for Cancer